Ischaemic colitis in rheumatoid arthritis patients receiving tumour necrosis factor-α inhibitors: An analysis of reports to the US FDA adverse event reporting system

Drug Safety

Volumn 36, Issue 5, 2013, Pages 329-334

  Salk, Allison ^a,b   Stobaugh, Derrick J ^a   Deepak, Parakkal ^a   Ehrenpreis, Eli D ^a  

^a NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CERTOLIZUMAB PEGOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; LISINOPRIL; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ARTICLE; COLON BIOPSY; COLONOSCOPY; COMORBIDITY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; FREEDOM OF INFORMATION ACT; HUMAN; ISCHEMIC COLITIS; MEDICAL DICTIONARY FOR REGULATORY ACTIVITIES; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COLITIS, ISCHEMIC; FEMALE; HUMANS; MALE; MIDDLE AGED; RESEARCH REPORT; TUMOR NECROSIS FACTOR-ALPHA; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84877745629     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-013-0041-y     Document Type: Article

References (26)

1. Cawthorn W, Sethi J. TNF-α and adipocyte biology. FEBS Lett. 2008;582(1):117-31.
2. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol. 1996;14:397-440.
3. Matsuno H, Yudoh K, Katayama R, et al. The role of TNF-alpha in the pathogenesis of inflammation and joint destruction in rheumatoid arthritis (RA): a study using a human RA/SCID mouse chimera. Rheumatology (Oxford). 2002;41(3):329-37.
4. Elliott MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum. 1993;36(12):1681-90.
5. Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet. 1994;344(8930):1105-10.
6. Segal B, Rhodus N, Patel K. Tumor necrosis factor (TNF) inhibitor therapy for rheumatoid arthritis. Oral Surg Oral Med Oral Pathol. 2008;106(6):276-84.
7. Brandt L, Boley S. AGA technical review on intestinal ischemia. Gastroenterology. 2000;118(5):954-68.
8. Lewis JH. The risk of ischaemic colitis in irritable bowel syndrome patients treated with serotonergic therapies. Drug Saf. 2011;34(7):545-65.
9. Sherid M, Ehrenpreis E. Types of colitis based on histology. Dis Mon. 2011;57(9):457-89.
10. Chang L, Tong K, Ameen V. Ischemic colitis and complications of constipation association with the use of alosetron under a risk management plan: clinical characteristics, outcomes, and incidences. Am J Gastroenterol. 2010;105(3):866-75.
11. Rasmussen D, Segars L. Case of ischemic colitis in a young adolescent associated with triphasic hormonal contraceptive therapy: a case report and review of the literature. W VA Med J. 2011;107(5):22-5.
12. Westgeest H, Akol H, Schreuder T. Pure naratriptan-induced ischemic colitis: a case report. Turk J Gastroenterol. 2010;21(1):42-4.
13. Dowd J, Bailey D, Moussa K, et al. Ischemic colitis associated with pseudoephedrine: four cases. Am J Gastroenterol. 1999;94(9):2430-4.
14. Gomella L, Gehrken G, Hagihara P, et al. Ischemic colitis and immunosuppression: an experimental model. Dis Colon Rectum. 1986;29(2):99-101.
15. Jarry A, Bach-Ngohou K, Masson D, et al. Human colonic myocytes are involved in postischemic inflammation through ADAM17-dependent TNFalpha production. Br J Pharmacol. 2006;147(1):64-72.
16. Kast RE, Altschuler EL. Both etanercept and infliximab can elevate tumor necrosis factor (TNF)-alpha and be the cause of treatment related new onset disease: the need to measure circulating TNF-alpha [letter]. J Rheumatol. 2008;35(8):1679 (author reply 1679-80).
17. Naranjo C, Busto U, Sellers E, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(20):239-45.
18. Gopalswamy S, Dindyal S, Arumugam P. A rare cause of ischemic colitis and review of literature. Internet J Gastroenterol. 2010;9(1):10.
19. Simsek I. TNF inhibitors: new and old agents for rheumatoid arthritis. Bull NYU Hosp Jt Dis. 2010;68(3):204-10.
20. Genta M, Genta R, Gabay C. Systemic rheumatoid vasculitis: a review. Semin Arthritis Rheum. 2006;36(2):88-98.
21. Nicola P, Maradit-Kremers H, Roger V, et al. The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. Arthritis Rheum. 2005;52(2):412-20.
22. Brandt LJ, Feuerstadt P. Intestinal ischemia. In: Feldman M, Friedman LS, Brandt LJ, editors. Sleisenger and Fordtran's gastrointestinal and liver disease. Philadelphia: Saunders; 2010. p. 2038.
23. Tehlirian C, Bathon J. Rheumatoid arthritis. In: Stone JH, Crofford LJ, White PH, editors. Primer on the rheumatic diseases. New York: Springer Science + Business Media; 2008. p. 114-41.
24. Gandhi M, Aweeka F, Greenblatt R, et al. Sex differences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol. 2004;44:499-523.
25. Song IH, Appel H, Haibel H, et al. New onset of Crohn's disease during treatment of active ankylosing spondylitis with etanercept. J Rheumatol. 2008;35:532-6.
26. Shakir SA, Layton D. Causal association in pharmacovigilance and pharmacoepidemiology: thoughts on the application of the Austin Bradford-Hill criteria. Drug Saf. 2002;25(6):467-71.